Summary
Becton Dickinson & Co. (BDX) reported solid revenue growth for the third quarter of fiscal year 2024, with total revenues increasing by 4.6% year-over-year to $5.045 billion. This growth was driven by broad-based strength across its segments, particularly the Interventional segment, which saw a 9.0% increase in revenue, and the Medical segment's 3.8% rise. Net income applicable to common shareholders rose to $537 million from $438 million in the prior year, and diluted Earnings Per Share (EPS) improved to $1.85 from $1.53. The company's financial condition remains robust, with operating cash flows of $1.369 billion for the first six months of fiscal 2024. BDX also continued to return capital to shareholders through dividends, distributing $550 million. Despite some headwinds such as increased raw material and labor costs, and specific market dynamics in China, the company demonstrated effective cost management, with selling, general, and administrative expenses decreasing as a percentage of revenue. The company's outlook remains focused on its BD 2025 strategy centered on growth, simplification, and empowerment.
Financial Highlights
53 data points| Revenue | $5.04B |
| Cost of Revenue | $2.74B |
| Gross Profit | $2.30B |
| R&D Expenses | $299.00M |
| SG&A Expenses | $1.19B |
| Operating Expenses | $4.31B |
| Operating Income | $734.00M |
| Interest Expense | $125.00M |
| Net Income | $537.00M |
| EPS (Basic) | $1.85 |
| EPS (Diluted) | $1.85 |
| Shares Outstanding (Basic) | 289.52M |
| Shares Outstanding (Diluted) | 290.34M |
Key Highlights
- 1Total revenues increased 4.6% to $5.045 billion for the three months ended March 31, 2024, compared to $4.821 billion in the prior year.
- 2Net income applicable to common shareholders increased to $537 million ($1.85 diluted EPS) from $438 million ($1.53 diluted EPS) in the prior year.
- 3The Interventional segment showed strong performance with a 9.0% revenue increase, driven by the Urology and Critical Care unit (up 26.1%) and Peripheral Intervention (up 4.3%).
- 4Operating cash flow for the six months ended March 31, 2024, was $1.369 billion, a significant increase from $584 million in the prior year.
- 5The company paid $550 million in dividends to common shareholders in the first six months of fiscal year 2024.
- 6Selling and administrative expenses as a percentage of revenue decreased in both the three-month and six-month periods, indicating improved operational efficiency.
- 7The company reported $3.222 billion in cash and equivalents and short-term investments as of March 31, 2024, providing strong liquidity.